Zymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc Buys 16,692 Shares

Zymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc bought 16,692 shares of the stock in a transaction on Thursday, December 26th. The stock was acquired at an average cost of $14.38 per share, for a total transaction of $240,030.96. Following the acquisition, the director now directly owns 14,720,931 shares in the company, valued at approximately $211,686,987.78. The trade was a 0.11 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Ecor1 Capital, Llc also recently made the following trade(s):

• On Tuesday, December 24th, Ecor1 Capital, Llc bought 11,958 shares of Zymeworks stock. The shares were bought at an average cost of $14.12 per share, for a total transaction of $168,846.96.

Zymeworks Price Performance

Shares of NYSE:ZYME opened at $14.50 on Friday. Zymeworks Inc. has a 12 month low of $7.97 and a 12 month high of $17.70. The company’s 50-day moving average price is $14.25 and its two-hundred day moving average price is $12.00. The firm has a market cap of $998.73 million, a P/E ratio of -9.67 and a beta of 1.12.

Zymeworks (NYSE:ZYME) last issued its quarterly earnings results on Thursday, October 31st. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.01. Zymeworks had a negative return on equity of 23.00% and a negative net margin of 182.75%. The business had revenue of $16.00 million for the quarter, compared to analyst estimates of $17.90 million. During the same quarter in the prior year, the firm posted ($0.41) earnings per share. The firm’s revenue for the quarter was down 3.1% compared to the same quarter last year. As a group, equities analysts predict that Zymeworks Inc. will post -1.43 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. Leerink Partners upgraded shares of Zymeworks from a “market perform” rating to an “outperform” rating and raised their price target for the stock from $10.00 to $25.00 in a research report on Thursday, November 7th. Stifel Nicolaus boosted their price target on Zymeworks from $21.00 to $28.00 and gave the company a “buy” rating in a research note on Monday, October 28th. Wells Fargo & Company upped their price target on Zymeworks from $12.00 to $14.00 and gave the company an “equal weight” rating in a report on Thursday, December 19th. Citigroup lifted their price objective on Zymeworks from $16.00 to $18.00 and gave the stock a “buy” rating in a report on Monday, November 4th. Finally, Leerink Partnrs upgraded Zymeworks from a “hold” rating to a “strong-buy” rating in a research note on Thursday, November 7th. Two research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $19.17.

Institutional Trading of Zymeworks

Institutional investors have recently bought and sold shares of the business. FMR LLC boosted its holdings in Zymeworks by 84.2% during the third quarter. FMR LLC now owns 3,336 shares of the company’s stock worth $42,000 after buying an additional 1,525 shares during the last quarter. DekaBank Deutsche Girozentrale acquired a new stake in shares of Zymeworks during the third quarter worth $47,000. Quest Partners LLC lifted its holdings in shares of Zymeworks by 8,049.6% in the second quarter. Quest Partners LLC now owns 9,209 shares of the company’s stock valued at $78,000 after purchasing an additional 9,096 shares in the last quarter. nVerses Capital LLC acquired a new position in Zymeworks during the 3rd quarter worth approximately $79,000. Finally, MQS Management LLC bought a new position in shares of Zymeworks in the 2nd quarter valued at about $92,000. Institutional investors and hedge funds own 92.89% of the company’s stock.

About Zymeworks

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.